PTGX stock: buy or sell?
January 24th, 2020
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs.
Should I buy PTGX stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading strategy that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Protagonist stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Protagonist Therapeutics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 2 ratings published for PTGX stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-2-22||BMO Capital Markets||n/a||Outperform|
PTGX stock analysis
Shares of Protagonist Therapeutics gained a fine 1.21% and closed at $7.52.
Protagonist Therapeutics gained a fine 1.21% and closed at $7.52. Since price and SMA200d lines crossed down on November, PTGX fell $-4.08 per share (-35.17%). From a daily perspective, PTGX is in a short term uptrend after plotting its last bottom ($6.64, on January 14th) higher than the previous bottom, and its last top ($7.66, on Wednesday) also over the previous top. Now trading in between its last bottom and last top PTGX might consolidate in a plain range, waiting to break out over $7.66 or down under $6.64.
After boosting a brilliant 5.07% in a week last week, Protagonist Therapeutics closed this week at $7.52 and jumped an excellent 3.01%. This week was the third green week in a row. Late December 2019 PTGX plunged a hair-raising -6.22% in just one week.
Since price and 40-weeks moving average lines crossed down early November, PTGX fell $-5.93 per share (-44.09%). Stocks below the 200 days moving average line are usually not recommended for average traders.
PTGX stock price history
PTGX IPO was on August 11th, 2016 at $12.00 per share1. Since then, PTGX stock declined a -37.30%, with a yearly average of -12.40%.
1: Adjusted price after possible price splits or reverse-splits.
PTGX stock historical price chart
PTGX stock reached 52-week highs on September at $16.67, and all-time highs 2016-12-06 with a price of 26.36.
PTGX stock price target is $20.00Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 2 price predictions for PTGX stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-2-22||BMO Capital Markets||Initiates||n/a||$17.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Protagonist Therapeutics presented its financial report, posting a super good growth for the Earnings per Share (EPS). Experts were expecting $-0.42 per share, but Protagonist posted $-0.57.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw an astounding growth of 54.14% to $30.93 million dollars. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) climbed a 58.34% to -125.87%.
|2017||$20 M||-||$-36.96 M-184.2%||-|
|2018||$31 M||54.14%||$-38.92 M-125.9%||5.32%|
Quarterly financial resultsProtagonist Therapeutics reported $2.35 million in revenues for 2018-Q4, a -61.53% decline compared to previous quarter. Reported quarter income marked $-13.87 M with a profit margin of -589.25%. Profit margin plummed a -446.45% compared to previous quarter when profit margin was -142.80%. When comparing turnover to same quarter last year, Protagonist sales marked a frightening correction and plunged a -79.14%. Looking back to recent quarterly results, Protagonist posted 2 negative quarters in a row.
|2017-Q3||$9 M||-||$-4.83 M-54.9%||-|
|2017-Q4||$11 M||28.48%||$-3.05 M-27.1%||-36.75%|
|2018-Q1||$11 M||-4.44%||$-7.66 M-71.1%||151.02%|
|2018-Q2||$12 M||8.28%||$-8.66 M-74.2%||13.08%|
|2018-Q3||$6 M||-47.60%||$-8.74 M-142.8%||0.83%|
|2018-Q4||$2 M||-61.53%||$-13.87 M-589.2%||58.73%|
Protagonist ownershipWhen you are planning to buy a company, it's worth to overview its ownership structure.
Protagonist shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 4.59% of all shares.
Bearish positions for PTGX stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$204.6 M|
|Total shares||27.2 M|
|Float shares||15.0 M|
|- Institutional holdings (%)||89.2%|
|- Insider holdings (%)||4.6%|
|Shares in short selling||0.0%|
|Friday, January 24th, 2020|
|Day range||$7.38 - $7.70|
|Average true range||$0.38|
|50d mov avg||$7.85|
|100d mov avg||$10.35|
|200d mov avg||$10.82|
Protagonist performanceTo measure stock performance is always good to compare with competitors or related stocks. We compared Protagonist Therapeutics against in the following table: